Group 1 - The company approved a profit distribution plan at the annual shareholders' meeting held on May 13, 2025, proposing a cash dividend of 20.00 yuan (including tax) for every 10 shares, resulting in a total cash dividend of 468,662,970.00 yuan for the 2024 fiscal year [1][2] - The distribution plan specifies that the cash dividend will not involve capital reserve transfers or stock bonuses, and the total share capital remains unchanged during the implementation period [1] - The dividend distribution will be executed on June 11, 2025, directly credited to shareholders' accounts through their securities companies or other custodians [3] Group 2 - The equity distribution is applicable to all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shenzhen Branch as of June 10, 2025 [1][3] - The company will not withhold individual income tax for certain shareholders, with tax rates varying based on the holding period of the shares [2][3] - The company assumes all legal responsibilities for any insufficient cash dividend distribution during the equity distribution application period [3]

证券代码：000915 股票简称：华特达因 编号：2025-026 山东华特达因健康股份有限公司 2024 年度权益分派实施公告 本公司及其董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、股东会审议通过的利润分配方案情况 1．山东华特达因健康股份有限公司（以下简称"本公司"或"公司"） 于 2025 年 5 月 13 日召开公司 2024 年年度股东会，审议通过了"公司 2024 年度利润分配及资本公积金转增股本预案"：以 2024 年 12 月 31 日的总股本 234,331,485 股为基数，向公司全体股东每 10 股派发现金 红利 20.00 元（含税），不以资本公积金转增股本，不送红股。2024 年度实际现金分红金额为 468,662,970.00 元人民币。（现金分红总金 额=实际参与分配的总股本×分配比例，即 234,331,485 股÷10 股×20.00 元=468,662,970.00 元人民币） 2．公司本次利润分配为固定比例方式分配。自分配方案披露至 实施期间，公司股本总额未发生变化。 3．本次实施的分配方案与公司 2024 年年度股东会审 ...

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [2] Core Viewpoints - The report emphasizes that the ASCO conference has catalyzed enthusiasm for innovative drug investments, with a notable increase in the number of presentations by Chinese experts [3][12] - It is believed that innovative drugs will remain the main focus of pharmaceutical investments in the medium to long term, driven by China's transition from quantity to quality and innovation in drug development, alongside increasing policy support [3][12] - Short-term factors such as US-China tariff disputes and geopolitical tensions may affect overall risk appetite, suggesting a focus on companies that can commercialize large-scale innovative drugs and those in the CXO and life sciences upstream sectors [3][12] Summary by Sections Market Performance - The pharmaceutical and biotechnology sector's weekly return was 2.21%, outperforming the CSI 300 by 3.30%, ranking second among 31 primary sub-industry indices [10] - The chemical pharmaceuticals sub-sector led with a weekly return of 3.83% [10][27] - Over the past month, the sector's return was 6.42%, again ranking second among sub-industry indices [10][17] Industry Dynamics - The report highlights the importance of the ASCO conference held from May 30 to June 3, 2025, in Chicago, which has further stimulated investment interest in innovative drugs [11][12] - The report suggests focusing on the CXO and life sciences upstream sectors, as well as traditional pharmaceutical companies transitioning from generics to innovative drugs [13][14] Recommendations - Companies to watch in the innovative drug chain include Tigermed, WuXi AppTec, and others in the CRO/CDMO space [13] - For the domestic recovery line, companies like Aier Eye Hospital and Tongrentang are recommended [13] - In the self-sufficiency line, high-end medical devices and research instruments from companies like Mindray and Hualan Biological Engineering are highlighted [14] Company-Specific Insights - The report identifies specific companies with strong growth potential, such as Yaoshi Bang, which is expected to achieve a CAGR of approximately 145% in net profit from 2024 to 2027 [15] - Kangchen Pharmaceutical has maintained a net profit growth rate of over 14% for the past three years, with a projected PE of about 8 times in 2025 [15] - Guoyuyuan is expected to see operational improvements in 2025, marking a potential turning point for the company [15][16]

Group 1 - The U.S. Court of Appeals has temporarily reinstated the tariff policy from the Trump administration, allowing the government to implement tariffs on multiple countries until further notice [2] - The court's decision comes after the U.S. International Trade Court had previously issued a ruling to prohibit the enforcement of these tariffs [2] Group 2 - Foreign investors are regaining confidence in Chinese assets, with some adjusting their positions to a higher allocation [3] - The recovery in confidence is attributed to the ongoing "value reassessment" of Chinese tech stocks and the expansion of service consumption [3] - Policies aimed at boosting consumption and domestic demand have drawn attention to the consumer sector [3] Group 3 - The Chinese Ministry of Foreign Affairs has condemned the U.S. decision to revoke student visas for Chinese students, claiming it harms their legitimate rights and disrupts cultural exchanges [4][5] - The ministry has expressed a desire for constructive actions to improve Sino-U.S. relations [5] Group 4 - The National Bureau of Statistics of China is working on guidelines for the "data factor ×" application scenarios to enhance economic and social development [6][7] - The initiative aims to leverage the multiplier effect of data elements [6] Group 5 - Domestic airlines in China will reduce fuel surcharges starting June 5, 2025, with specific adjustments based on flight distance [9] - This reduction is expected to stimulate consumer demand as the summer travel season approaches [9] Group 6 - Nezha Auto's debt-to-equity swap plan has failed, with only partial debt relief achieved, leading to significant operational changes including the removal of its logo from its headquarters [12][13] - The company is reportedly relocating to a smaller office due to reduced staff [13] Group 7 - The human-robot industry is seeing potential IPO activity, with Yushutech changing its name to indicate a possible transition to a public company [13] - This name change is viewed as a routine operational adjustment, although it raises speculation about future funding [13] Group 8 - The renewable energy sector is reaching a critical point with significant transformations in operations and trading [14] - The camping economy is gaining attention, with companies actively positioning themselves in this growing market [14] - The film industry has seen a total box office exceeding 1.5 billion yuan in May, with many films set for the summer release [14] Group 9 - A-share market indices showed positive performance, with the Shanghai Composite Index closing at 3363.45 points, up 0.70% [14] - The Hong Kong stock market also experienced gains, particularly in the technology sector, with the Hang Seng Tech Index rising by 2.46% [15] Group 10 - Analysts predict that the A-share market will face some pressure in June but expect a solid bottom, with a positive outlook for Chinese assets [16][17] - There is an anticipated shift in foreign capital allocation towards A-shares, driven by stable economic conditions and low market valuations [17]

本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 山东华特达因健康股份有限公司子公司山东达因海洋生物制药股 份有限公司（以下简称"达因药业"）近日收到国家药品监督管理局（以 下简称"国家药监局"）核准签发的《药物临床试验批准通知书》。现将 有关信息披露如下： | 药物名称 | 异丙托溴铵吸入气雾剂 | | --- | --- | | 批件类别 | 药物临床试验批准通知书 | | 受理号 | CXHL2500061 | | 批件号 | 2025LP01446 | | 剂型 | 气雾剂 | | 申请事项 | 国产药品注册 | | 注册分类 | 化学药品注册分类 4 类 | | 申请人 | 山东达因海洋生物制药股份有限公司 | | 审批结论 | 根据《中华人民共和国药品管理法》及有关规定，经审查，符 合药品注册的有关要求，同意本品开展用于预防和治疗与慢 性阻塞性气道疾病相关的呼吸困难：慢性阻塞性支气管炎伴 或不伴有肺气肿；轻到中度支气管哮喘的临床试验。 | 一、药物临床试验批准通知书基本内容 证券代码：000915 证券简称：华特达因 公告编号：2025-025 山东 ...

Core Viewpoint - The company, Watson, has received approval from the National Medical Products Administration for a clinical trial of a new drug, indicating a significant step in its product development pipeline [1] Group 1: Drug Approval - Watson's subsidiary, Dain Pharmaceutical, has been granted a "Drug Clinical Trial Approval Notice" for the drug named Isopropyl Bromide Inhalation Aerosol [1] - The drug is classified as a Class 4 chemical drug and is intended for the prevention and treatment of respiratory difficulties associated with chronic obstructive airway diseases, chronic bronchitis with or without emphysema, and mild to moderate bronchial asthma in both children and adults [1] Group 2: Next Steps - Following the approval of the clinical trial, the company must conduct clinical trials before applying for production and market approval from the National Medical Products Administration [1]

Core Viewpoint - The regulatory authorities in China are intensifying their scrutiny of the misuse of funds by listed companies, particularly focusing on the actions of major shareholders and actual controllers who exploit company resources for personal gain [1][2][3]. Regulatory Actions - The China Securities Regulatory Commission (CSRC) has introduced new rules requiring listed companies to promptly demand the return of misappropriated funds and disclose the reasons for such actions, their impact on the company, and the rectification plans [1][2]. - As of May 28, 2023, there have been 48 administrative measures or penalties against 37 companies related to fund misuse, including warnings, fines, and orders for correction [1][2]. Enforcement Against Major Shareholders - The regulatory bodies are targeting the "key minority," which includes major shareholders and executives who engage in fund misappropriation, with a focus on both direct and indirect methods of fund occupation [2][3]. - Specific cases, such as the reprimand of ST Dongshi for failing to return 106 million yuan of raised funds, illustrate the ongoing enforcement actions against individuals involved in fund misuse [2][3]. Accountability Mechanisms - The regulatory framework emphasizes that misappropriated funds must be returned, with strict deadlines for rectification and potential delisting for non-compliance [4][5]. - Companies are encouraged to utilize legal measures, such as lawsuits and asset freezes, to recover misappropriated funds, ensuring the protection of minority shareholders [5][6]. Independent Oversight - Independent directors are actively involved in urging management to recover misappropriated funds, as seen in the case of ST Changkang, where independent directors issued a reminder to address fund occupation issues [6]. - The China Securities Investor Services Center is promoting collective and derivative lawsuits to enhance investor protection and ensure accountability for fund misuse [6].

Market Performance - The pharmaceutical sector rose by 0.42% on May 23, 2025, outperforming the CSI 300 index by 1.23 percentage points, ranking second among 31 sub-industries in the Shenwan classification [1] - Among sub-industries, medical devices (+1.43%), medical research outsourcing (+0.98%), and offline pharmacies (+0.74%) performed well, while vaccines (-0.68%), blood products (-0.43%), and hospitals (-0.27%) lagged [1] - Top three gainers in individual stocks were Xintiandi (+20.02%), Haichen Pharmaceutical (+20.00%), and Duori Pharmaceutical (+20.00%), while the top three losers were Yahong Pharmaceutical (-5.86%), BeiGene (-4.15%), and Runduo Co., Ltd. (-3.94%) [1] Industry News - GSK announced that the FDA approved its first-in-class antibody therapy Nucala (Mepolizumab) for use as an adjunct maintenance treatment in adults with eosinophilic phenotype, poorly controlled chronic obstructive pulmonary disease (COPD) [2] - Nucala is a monoclonal antibody targeting IL-5, developed for a range of IL-5 mediated diseases, and is the first biologic approved for this specific COPD patient population characterized by blood eosinophil count (BEC) ≥150 cells/μL [2] Company News - Kelun Pharmaceutical (002422) announced that its subsidiary Kelun Botai received an upfront payment from Windward Bio as part of an exclusive licensing agreement for SKB378/HBM9378/WIN3781, including cash received in February 2025 and equity from Windward Bio's parent company, which will be delivered upon regulatory approval in China [3] - Jiuzhou Pharmaceutical (603456) reported that its subsidiary Drug Technology passed an FDA cGMP inspection conducted from March 17 to 21, 2025, and received the FDA's Establishment Inspection Report (EIR) confirming compliance [3] - Huate Dain (000915) announced that its subsidiary Dain Pharmaceutical received a drug registration certificate for sodium valproate oral solution from the National Medical Products Administration, confirming that the product meets registration requirements [3] - Dizh Pharmaceutical (688192) announced that it will present three latest research advancements on its two self-developed innovative drugs DZD8586 and DZD6008 at the 2025 American Society of Clinical Oncology (ASCO) annual meeting, focusing on B-cell non-Hodgkin lymphoma (B-NHL) and non-small cell lung cancer (NSCLC) [4]

Group 1 - China Communication Technology Co., Ltd. won a total of 11 important rail transit projects with a total bid amount of approximately 3.789 billion yuan, accounting for 11.67% of the company's audited revenue for 2024 [1] - New Chai Co., Ltd. plans to use no more than 500 million yuan of idle funds to purchase low-risk financial products to improve fund efficiency [2] - Qingshan Paper Industry's controlling shareholder intends to restructure and inject assets into Fujian Provincial Industrial Holding Group [3] Group 2 - BWS hired Liu Xiaodan as Senior Vice President, effective immediately [4] - Huakang Clean won a bid for a purification project at the Tengzhou Medical and Health Center, with a bid price of 60.2394 million yuan [6] - Silver Dragon Co., Ltd. announced that several executives plan to reduce their holdings by a total of no more than 550,000 shares due to personal financial needs [8] Group 3 - Intercontinental Oil & Gas plans to invest 848 million USD in the South Basra Integrated Project in Iraq, holding a 67% stake [13] - Huatai Dain's subsidiary received a drug registration certificate for sodium valproate oral solution, used for treating epilepsy [14] - Hainan Mining's 20,000-ton battery-grade lithium hydroxide project has achieved full-process connectivity and produced qualified products [29] Group 4 - Roman Co., Ltd.'s subsidiary won a significant overseas project in Saudi Arabia with a bid amount of approximately 200 million yuan [30] - Measurement Co., Ltd. completed a capital reduction for its subsidiary, optimizing resource allocation [31] - Guodian Nanzi plans to increase capital by 45 million yuan for its wholly-owned subsidiary to meet market expansion needs [32] Group 5 - Eighty Billion Space plans to repurchase shares with a total amount not less than 50 million yuan and not exceeding 100 million yuan [33] - Tianyin Electromechanical's director plans to reduce holdings of no more than 0.25% of the company's shares [34] - Hailier's subsidiary passed environmental protection acceptance for its agricultural chemical preparation project [35] Group 6 - Kelong Pharmaceutical's subsidiary will present innovative drug research results at the ASCO annual meeting [36] - Zhonghong Medical's subsidiary received medical device registration certificates for enteral nutrition pumps and injection pumps [37] - Luyou Pharmaceutical received a drug registration certificate for amlodipine besylate tablets, used for hypertension [39]

本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 证券代码：000915 证券简称：华特达因 公告编号：2025-024 山东华特达因健康股份有限公司 关于子公司达因药业获得药品注册证书的公告 三、获得药品注册证书对公司的影响及风险提示 药品名称 丙戊酸钠口服溶液 主要成分 丙戊酸钠 剂型 口服溶液剂 申请事项 药品注册（境内生产） 规格 40ml：8g 注册分类 化学药品 4 类 药品注册标准编号 YBH10372025 药品有效期 24 个月 包装规格 1 瓶/盒 处方药/非处方药 处方药 上市许可持有人 山东达因海洋生物制药股份有限公司 生产企业 山东达因海洋生物制药股份有限公司 药品批准文号 国药准字 H20254187 药品批准文号有效期 至 2030 年 05 月 12 日 一、 药品注册证书基本情况 达因药业获得丙戊酸钠口服溶液 药品注册证书》，进一步丰富 了公司儿童用药产品管线，有助于公司发展战略的实现和竞争力的增 强，对公司致力于儿童健康事业和业绩的提升将产生积极影响。 药品销售易受到国内医药行业政策变动、招标采购、市场环境变 化等因素影响，存 ...